Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial-Reference-Cited by-同舟云学术

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Published:2019-05-28 Issue:17 Volume:25 Page:5212-5220
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Li Qiao,Guan Xiuwen,Chen Shanshan,Yi Zongbi,Lan Bo,Xing Puyuan,Fan Ying,Wang Jiayu,Luo Yang,Yuan Peng,Cai Ruigang,Zhang Pin,Li Qing,Zhong Dafang,Zhang Yifan,Zou Jianjun,Zhu Xiaoyu,Ma Fei,Xu Binghe

Funder

ClinicalTrials.gov

Jiangsu Hengrui Pharmaceutical CO. LTDNational Nature Science Foundation of China

CAMS

Ministry of Science and Technology

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study;Neoplasia;2024-10

2. Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases;Frontiers in Pharmacology;2024-08-19

3. Case report: Pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma;Frontiers in Oncology;2024-07-09

4. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

5. Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer;Journal of Chemotherapy;2024-04